Eikon Therapeutics, Inc. (EIKN) Stock Price & Analysis
Eikon Therapeutics, Inc. (EIKN) fell 2.34% to USD 8.77 as of June 10, 2026 at 11:25 UTC, according to Nexqual real-time market data.
EIKN last closed at USD 8.98; the session ranged USD 8.51–9.46 on volume of 204,985 shares. Market capitalization is $474.80M, with a 52-week range of USD 7.9–17.4 (NMS). Source: Nexqual, June 10, 2026 at 11:25 UTC.
Key Statistics (as of June 10, 2026 at 11:25 UTC)
| Price | USD 8.77 |
|---|---|
| Change | ▼ 2.34% (down) |
| Previous Close | USD 8.98 |
| Open | USD 9.06 |
| Day Range | USD 8.51 – 9.46 |
| 52-Week Range | USD 7.9 – 17.4 |
| Volume | 204,985 shares |
| Market Cap | $474.80M |
| Exchange | NMS |
Technical Analysis (EIKN)
Nexqual's technical model rates EIKN "SELL" based on 1 bullish and 5 bearish signals across 85 daily candles, as of June 10, 2026 at 11:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.46 (neutral) |
| vs SMA50 | Below (USD 10.3) |
| MACD | -0.38 (negative) |
Analyst Ratings (EIKN)
Wall Street analysts rate EIKN "Buy" based on 5 analysts, with a mean price target of USD 24.8 (range USD 5–32), per Nexqual as of June 10, 2026 at 11:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 24.8 |
| High Target | USD 32 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 0 / 1 |
Earnings (EIKN)
| Next Earnings Date | 2026-05-11 |
|---|---|
| EPS Estimate | USD -1.46 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.46 vs est -1.22 ▼ miss |
| 2025-12-31 | USD -26.23 vs est -17.75 ▼ miss |
Source: Nexqual, June 10, 2026 at 11:25 UTC.
Financials & Fundamentals (EIKN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 46.28 |
| Current Ratio | 11.75 |
| Total Cash | $512.18M |
| Total Debt | $254.83M |
Source: Nexqual, June 10, 2026 at 11:25 UTC.
Financial Health Score (EIKN)
Nexqual rates Eikon Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 11:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $512M cash vs $255M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$224M |
| Efficiency | Mixed — No data |
Ownership (EIKN)
| Insider Ownership | +17.39% |
|---|---|
| Institutional Ownership | +64.24% |
| Shares Outstanding | 54.14M |
| Float | 28.03M |
| Short % of Float | +9.98% |
Source: Nexqual, June 10, 2026 at 11:25 UTC.
Leadership (EIKN)
Eikon Therapeutics, Inc. is led by Roger M. Perlmutter (age 73), Chairman, President & CEO, per Nexqual as of June 10, 2026 at 11:25 UTC.
| Chairman, President & CEO | Roger M. Perlmutter (age 73) |
|---|---|
| Chief Operating Officer | Michael A. Klobuchar (age 49) |
| Treasurer & CFO | Alfred Lloyd Bowie Jr. (age 43) |
| Chief Technology Officer | Russ Berman |
Major Backers & Investors (EIKN)
Notable institutional backers of Eikon Therapeutics, Inc. include FMR, LLC, Foresite Capital Management IV, LLC, T. Rowe Price, according to Nexqual as of June 10, 2026 at 11:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 7.09% |
| Foresite Capital Management IV, LLC | 6.03% |
| T. Rowe Price | 4.23% |
| Fidelity | 4.23% |
| Merck & Co., Inc. | 3.08% |
| Price (T.Rowe) Associates Inc | 2.66% |
| Capital Group | 2.11% |
| SmallCap World Fund Inc | 2.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.46% |
| Vanguard Group | 3.1% |
Source: Nexqual, June 10, 2026 at 11:25 UTC.
From Eikon Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States.
- It develops medicines to address serious unmet medical needs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGMB | AgomAb Therapeutics NV | USD 9.8 | ▼ 1.21% |
| MANE | Veradermics, Incorporated | USD 95.91 | ▲ 4.6% |
| GENB | Generate Biomedicines, Inc. | USD 13.19 | ▲ 2.49% |
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:25 UTC. This page is informational and not investment advice.